Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Main Article Content

Michael Migden
University of Texas MD Anderson Cancer Center, Houston, TX, USA

Danny Rischin
Peter MacCallum Cancer Centre, Melbourne, Australia

Medha Sasane
Sanofi, Bridgewater Township, NJ, USA

Vera Mastey
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Anna Pavlick
New York University Langone Medical Center, New York, NY, USA

Chrysalyne Schmults
Brigham and Women?s Hospital, Harvard Medical School, Boston, MA, USA

Zhen Chen
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Alexander Guminski
Royal North Shore Hospital, Sydney, Australia

Axel Hauschild
Schleswig-Holstein University Hospital, Kiel, Germany

Denise Bury
Sanofi, Cambridge, MA, USA

Stacie Hudgens
Clinical Outcomes Solutions, Tucson, AZ, USA

Anne Lynn Chang
Stanford University School of Medicine, Redwood City, CA, USA

Guilherme Rabinowits
Miami Cancer Institute/Baptist Health South Florida, Miami, FL, USA

Sherrif Ibrahim
Rochester Medical Center, Rochester, NY, USA

Matthew Fury
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Israel Lowy
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Siyu Li
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA

Chieh-I Chen
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Keywords

Basal Cell Carcinoma, BCC, Biologic, Cemiplimab, Quality of Life, Pain

Abstract

Abstract not available.

References

1. Mills KC et al. Arch Dermatol. 2012;148:1422–1423.

2. Ahmed SR et al. Expert Rev Clin Pharmacol. 2019;12:947–951.

3. Migden MR et al. N Engl J Med. 2018;379:341–351.

4. Rischin D et al. Ann Oncol. 2019;30(suppl):536–537.

5. Migden MR et al. J Clin Oncol. 2019;37(suppl):6015.

6. Migden MR et al. Lancet Oncol. 2020;21:294–305.

7. Eisenhauer et al. Eur J Cancer. 2009;45:228–247.

8. Aaronson NK et al. J Natl Cancer Inst. 1993;85:365–376.

9. Osoba D et al. J Clin Oncol. 1998;16:139–144.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.5

Article Details

How to Cite
Migden, M., Rischin, D., Sasane, M., Mastey, V., Pavlick, A., Schmults, C., Chen, Z., Guminski, A., Hauschild, A., Bury, D., Hudgens, S., Chang, A. L., Rabinowits, G., Ibrahim, S., Fury, M., Lowy, I., Li, S., & Chen, C.-I. (2021). Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial. SKIN The Journal of Cutaneous Medicine, 5(1), s5. https://doi.org/10.25251/skin.5.supp.5
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Poster Presentations from WC21 Clinical Dermatology Conference®: Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 > >>